First patient's metastases vanish after Russian oncovaccine

Metastases have disappeared in the first patient who received the oncovaccine.

Consensus

The first patient treated with the Russian oncovaccine had metastases disappear.
The patient has been monitored monthly for four months with no new growths detected.
The patient will continue monthly observation for three years.
The oncovaccine is based on mRNA technology and trains the immune system to destroy cancer and metastases.
An individualized vaccine is created for each patient using their genetic data.
The vaccine is developed at the National Research Center for Epidemiology and Microbiology named after N.F. Gamalei.

The oncologist Evgeny Cheremushkin stated that it is too early to conclude definitive results based on a single clinical case, as statistical validity requires a full control group. — vm
Cheremushkin emphasized that the potential for accelerated approval depends on the results, which could lead to faster registration, inclusion in OMS, or special funding. — vm
Cheremushkin noted that experimental immunotherapy is only allowed after standard treatments fail or disease progresses. — vm
Cheremushkin mentioned that some oncovaccines have shown good results in clinical practice and experiments for certain cancer types and advanced stages. — vm
Academician Andrey Krapin conducts high-resolution CT scans (up to tenths of a millimeter) focusing on lymph nodes and the entire body from head to toe. — riamo
Gintburg stated that the patient has been in stable condition for four months and no new growths were found as of the previous day. — riamo
Gintburg said the patient has been monitored for four months with no new formations detected. — tg_tass_agency
Gintburg confirmed that no new formations were found after four months of observation. — vesti